Peroxisome Proliferator-Activated Receptor-α Regulates Fatty Acid Utilization in Primary Human Skeletal Muscle Cells
- Deborah M. Muoio12,
- James M. Way3,
- Charles J. Tanner2,
- Deborah A. Winegar3,
- Steven A. Kliewer3,
- Joseph A. Houmard2,
- William E. Kraus1 and
- G. Lynis Dohm2
- 1Department of Medicine and Cell Biology, Duke University Medical Center, Durham, North Carolina
- 2Department of Biochemistry and the Human Performance Laboratory, East Carolina University, Greenville, North Carolina
- 3Departments of Molecular Endocrinology and Metabolic Diseases, GlaxoSmithKline, Research Triangle Park, North Carolina
Abstract
In humans, skeletal muscle is a major site of peroxisome proliferator–activated receptor-α (PPAR-α) expression, but its function in this tissue is unclear. We investigated the role of hPPAR-α in regulating muscle lipid utilization by studying the effects of a highly selective PPAR-α agonist, GW7647, on [14C]oleate metabolism and gene expression in primary human skeletal muscle cells. Robust induction of PPAR-α protein expression occurred during muscle cell differentiation and corresponded with differentiation-dependent increases in oleate oxidation. In mature myotubes, 48-h treatment with 10–1,000 nmol/l GW7647 increased oleate oxidation dose-dependently, up to threefold. Additionally, GW7647 decreased oleate esterification into myotube triacylglycerol (TAG), up to 45%. This effect was not abolished by etomoxir, a potent inhibitor of β-oxidation, indicating that PPAR-α–mediated TAG depletion does not depend on reciprocal changes in fatty acid catabolism. Consistent with its metabolic actions, GW7647 induced mRNA expression of mitochondrial enzymes that promote fatty acid catabolism; carnitine palmityltransferase 1 and malonyl-CoA decarboxylase increased ∼2-fold, whereas pyruvate dehydrogenase kinase 4 increased 45-fold. Expression of several genes that regulate glycerolipid synthesis was not changed by GW7647 treatment, implicating involvement of other targets to explain the TAG-depleting effect of the compound. These results demonstrate a role for hPPAR-α in regulating muscle lipid homeostasis.
Footnotes
-
Address correspondence and reprint requests to Deborah M. Muoio, P.O. Box 3327, Duke University Medical Center, Durham, NC 27710. E-mail: muoio{at}duke.edu.
Received for publication 22 August 2001 and accepted in revised form 4 January 2002.
D.M.M. has received funding from GlaxoSmithKline to support studies focused on developing new drug therapies to treat muscle insulin resistance.
ACO, acyl-CoA oxidase; ASM, acid-soluble metabolite; CPT1, carnitine palmityltransferase 1; DFM, differentiation media; DGAT, diacylglycerol acyltransferase; DMEM, Dulbecco’s modified Eagles medium; FBS, fetal bovine serum; GM, growth media; GPAT, glycerol-3-phosphate acyltransferase; HSKMC, human skeletal muscle cell; MCAD, medium-chain acyl-CoA dehydrogenase; MCD, malonyl-CoA decarboxylase; PDH, pyruvate dehydrogenase; PDHK, PDH kinase; PPAR, peroxisome proliferator–activated receptor; RTQ-PCR, real-time quantitative PCR; SREBP1, sterol regulatory element binding protein 1; TAG, triacylglycerol; TCA, tricarboxylic acid.
- DIABETES











